Legend Biotech Corporation
LEGN
$34.18
-$0.52-1.50%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 66.60% | 151.27% | 149.90% | 189.43% | 251.64% |
| Total Other Revenue | 1,378.95% | 3,746.03% | 5,844.64% | -78.65% | -69.35% |
| Total Revenue | 66.86% | 154.36% | 158.67% | 187.57% | 250.91% |
| Cost of Revenue | 8.37% | 26.94% | 29.21% | 33.18% | 7.20% |
| Gross Profit | 121.27% | 142.53% | 26.68% | 22.89% | 57.78% |
| SG&A Expenses | 61.72% | 33.01% | 39.82% | 18.82% | 16.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.29% | 28.62% | 31.86% | 28.35% | 9.57% |
| Operating Income | 23.96% | 59.77% | 5.20% | 5.86% | 36.06% |
| Income Before Tax | -93.43% | 90.96% | 46.60% | -8.17% | 26.31% |
| Income Tax Expenses | 1,639.93% | -22.07% | -96.09% | -1,403.27% | -289.47% |
| Earnings from Continuing Operations | -101.46% | 90.86% | 46.66% | -6.58% | 26.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -101.46% | 90.86% | 46.66% | -6.58% | 26.78% |
| EBIT | 23.96% | 59.77% | 5.20% | 5.86% | 36.06% |
| EBITDA | 24.34% | 61.63% | 5.06% | 6.17% | 36.62% |
| EPS Basic | -99.53% | 91.23% | 51.58% | 3.27% | 34.72% |
| Normalized Basic EPS | -91.54% | 91.33% | 51.45% | 2.08% | 34.29% |
| EPS Diluted | -99.53% | 91.23% | 51.69% | 3.15% | 34.72% |
| Normalized Diluted EPS | -91.54% | 91.33% | 51.45% | 2.08% | 34.29% |
| Average Basic Shares Outstanding | 0.96% | 4.19% | 10.14% | 10.18% | 12.18% |
| Average Diluted Shares Outstanding | 0.96% | 4.19% | 10.14% | 10.18% | 12.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
